{
Pfizer Inc.

Companies

}
001122334455554433221100
001122334455554433221100

emerging therapies and market dynamics for acute bacterial skin infections

DelveInsight's report on Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) forecasts significant market growth by 2034, driven by rising prevalence and awareness. Key players include Glenmark Pharma and AbbVie, with therapies like Zevtera and Dalbavancin leading the charge. The report highlights a higher incidence in men and notes nearly 870,000 hospital admissions in the U.S. due to ABSSSI in 2004.
openPR.com
Merck & Co., Inc. Wockhardt Limited Pfizer Inc. Glenmark Pharmaceuticals Limited Allergan plc Novartis AG JPN FRA GBR ESP USA DEU ITA Gaurav Bora Show more
Healthcare, Market Report
19:35 23.12.2024

neostigmine methylsulfate injection market growth driven by chronic conditions and surgeries

The global Neostigmine Methylsulfate Injection Market, valued at $156.54 million in 2022, is projected to reach $228.43 million by 2031, growing at a CAGR of 4.4%. The rise in chronic conditions like myasthenia gravis and increased surgical procedures are driving market expansion, particularly in North America and emerging markets. Key players include Pfizer, Fresenius Kabi, and Hikma Pharmaceuticals, with ongoing developments in combination therapies enhancing treatment options.
openPR.com
United States Dollar Fresenius Kabi AG SUN Pharmaceutical Industries Ltd. Hikma Pharmaceuticals PLC Pfizer Inc. Bausch Health Companies Inc. Endo International Ltd. Baxter International Inc. FRA KOR GBR ESP USA DEU ITA CAN CHN IND BRA ARG ZAF JPN MEX Mylan Nv Show more
Healthcare, Market Report
08:28 23.12.2024

two healthcare dividend stocks to consider during market volatility

As 2024 closes with the S&P 500 achieving a 25% return, investors are advised to consider defensive strategies amid potential market volatility. AbbVie, with a strong dividend yield and promising drug sales growth, and Pfizer, offering a high yield and new growth drivers, are highlighted as solid healthcare sector investments for uncertain times. Both companies are well-positioned for continued success as they enter 2025.
The Motley Fool
United States Dollar ABBVIE Pfizer Inc. USA
Healthcare, Market Report
12:50 22.12.2024

navigating a pricey stock market strategies for 2025 investment success

Wall Street is experiencing one of its priciest stock markets in history, with the S&P 500's Shiller P/E ratio nearing 39, significantly above the historical average of 17.19. This elevated valuation raises concerns about potential volatility and declines in 2025, prompting a strategy of holding 15% to 30% of portfolios in cash to capitalize on future buying opportunities. Historical trends indicate that when the Shiller P/E exceeds 30, significant market corrections often follow.
The Motley Fool
United States Dollar Pfizer Inc.
Finance & Economy, Market Report
11:06 21.12.2024

global uveitis treatment market poised for significant growth by 2032

The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
openPR.com
Pfizer Inc. Bayer AG Novartis AG Regeneron Pharmaceuticals, Inc. Merck & Co., Inc. CIPLA LTD Lupin Limited Hoffmann-La Roche AG Bausch Health Companies Inc. BIOGEN ABBVIE Alimera Sciences Inc. SAU ISR FRA RUS DEU TWN ARG ARE AUT TUR SGP NZL CHL USA BRA CAN ITA JPN IDN GBR ESP IND MYS COL AUS THA EGY VNM KOR PHL CHN ZAF MEX Nidhi Bhavsar Show more
Healthcare, Market Report
20:41 19.12.2024

China's ensartinib gains FDA approval for lung cancer treatment

Xcovery Holdings' ensartinib, branded as Ensacove, has received FDA approval as a first-line treatment for ALK-positive non-small cell lung cancer, marking a significant milestone as the first innovative targeted lung cancer drug from a Chinese company to enter the U.S. market. While it shows a 44% reduction in progression or death compared to Pfizer's Xalkori, it faces stiff competition from established ALK inhibitors like Roche's Alecensa, which has demonstrated superior efficacy in previous studies. Despite its potential, Ensacove's market entry comes amid a landscape dominated by major pharmaceutical players.
Fierce Pharma
United States Dollar Chinese Yuan Swiss Franc Japanese Yen AstraZeneca PLC Hoffmann-La Roche AG Pfizer Inc. Novartis AG CHN USA JPN Show more
Healthcare, Market Report
16:20 19.12.2024

UBS maintains neutral rating on Pfizer amid lung cancer study concerns

UBS has maintained a "Neutral" rating for Pfizer, setting a target price of $31. The decision to terminate the lung cancer study with Sasanlimab is attributed to strategic reasons, though high dropout rates raise concerns, particularly regarding the ongoing phase III bladder cancer study.
boerse.de
United States Dollar Pfizer Inc. USA Warren Buffett Trung Huynh
Healthcare, Market Report
08:26 19.12.2024

pfizer receives neutral rating from ubs amid diverse product portfolio

Pfizer Inc., the leading pharmaceutical group, has received a Neutral rating from UBS. Its net sales are primarily driven by primary care products (52.3%), followed by specialty care (25.6%) and oncology (19.9%). Geographically, sales are distributed with 42.3% in the U.S., 21.9% in Europe, and 33.8% in other regions.
MarketScreener
United States Dollar Pfizer Inc. USA
Healthcare, Market Report
08:13 19.12.2024

stocks decline as dow experiences longest losing streak since 1978

U.S. stocks fell on Tuesday, with the Dow experiencing its longest losing streak since February 1978, dropping for the ninth consecutive session. Investors are cautious ahead of the Federal Reserve's policy announcement, anticipating a 25 basis point rate cut, while economic data shows solid consumer spending. The S&P 500 and Nasdaq also declined, though Tesla's stock rose significantly after a price target increase.
Reuters
United States Dollar Tesla, Inc. Pfizer Inc. USA Jerome Powell Richard Chang Jason Ware Lisa Pauline Mattackal Brendan Mcdermid Purvi Agarwal Show more
Finance & Economy, Market Report
22:24 17.12.2024

dow jones faces longest losing streak since 1970s amid economic concerns

Investors are concerned that Trump's potential trade tariffs could exacerbate inflation, as retail sales rose 0.7% in November. The Dow Jones is on track for its longest losing streak since the 1970s, while Nvidia faces challenges with thermal issues in its chips, impacting its stock. Tesla continues to rise, with analysts projecting a bullish outlook for 2025.
Investor's Business Daily
United States Dollar Berkshire Hathaway Inc. Pfizer Inc. Heico Corp Alphabet Inc. Tesla, Inc. Broadcom Inc. Amazon.com, Inc. Metagenomi, Inc. FedEx Corp Lennar Corp NIKE, Inc. Microsoft Corp Apple Inc. NVIDIA Corporation USA Warren Buffett Dan Ives Timothy Arcuri Ming-chi Kuo Donald Trump Show more
Finance & Economy, Market Report
18:30 17.12.2024
Trending
Subcategory
Corporate News Industry Trends Central Banks and Digital Currencies Cryptocurrency Trends Fintech Startups Industry Mergers & Acquisitions Startups & Entrepreneurship AI Innovations Emerging Startups Funding Rounds & Investments
Countries:
FRA CHN ARE USA
Companies:
Tencent Music Entertainment Group Sony Music Entertainment COMPANY Alphabet Inc. Microsoft Corporation Corp. Oracle Corporation Softbank Group Corp.
Currencies:
United States Dollar
People:
Sean Parker Frank Abagnale, Sr. Rod Tidwell Billy Beane Ray Kinsella Blake Lively Harry Callahan Frank Lucas

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.